What does CNS Pharmaceuticals, Inc. do?
CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, engages in the development of therapies for neurology and oncology diseases in the United States. It develops TPI 287, an investigational chemotherapy agent, which is in Phase II clinical trial for the treatment of glioblastoma, metastatic breast cancer…
What is CNS Pharmaceuticals, Inc.'s P/E and P/B ratio?
CNS Pharmaceuticals, Inc. has a P/E ratio of -0.3 and a P/B ratio of 0.38.
What is CNS Pharmaceuticals, Inc.'s debt-to-equity ratio?
CNS Pharmaceuticals, Inc. has a debt-to-equity ratio of 0.07.
How much does CNS Pharmaceuticals, Inc. owe compared with what it owns?
CNS Pharmaceuticals, Inc. owes $0.17 for every $1 it owns (balance sheet Jun 2026), which is low.
What is CNS Pharmaceuticals, Inc.'s Positivity rank?
CNS Pharmaceuticals, Inc. is ranked #2,431 of 6,774 companies globally and #775 of 4,000 in United States on PositoAI, with a Positivity Score of 21,521.
Does CNS Pharmaceuticals, Inc. have any regulatory orders, red flags (PosiRed) or yellow flags (PosiYellow)?
No active red flags (PosiRed) or yellow flags (PosiYellow) are currently on record for CNS Pharmaceuticals, Inc..
Where can I read the latest news about CNS Pharmaceuticals, Inc.?
Recent headlines about CNS Pharmaceuticals, Inc. from the last 30 days, with links to the original articles, are on its News page on PositoAI.
Does CNS Pharmaceuticals, Inc. have a PositoAI PosiShot or QR code?
Yes. A dated PosiShot of CNS Pharmaceuticals, Inc.'s current position, a PosiQR code for its live profile and a ready-made dated mention are available on its For this company page on PositoAI.